Literature DB >> 18779746

Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.

David M Calderhead1, Mark A DeBenedette, Helen Ketteringham, Alicia H Gamble, Joe M Horvatinovich, Irina Y Tcherepanova, Charles A Nicolette, Don G Healey.   

Abstract

Dendritic cells (DC) for the immunotherapy of cancer and infectious disease require the appropriate maturation and activation signals to effectively present antigen to drive a proinflammatory response. Here we present a comparison of 4 different maturation protocols for antigen-encoded mRNA electroporated DC. Two protocols rely on cytokine-induced maturation given either preelectroporation or postelectroporation. In addition to the cytokine treatment, 2 further maturation protocols use coelectroporation of CD40L mRNA, with antigen-encoding RNA, to deliver CD40 signals. There were no significant differences in expression of costimulatory molecules such as CD80, CD83, and CD86 or the levels of expression of major histocompatibility complexes. However, results indicate that delivery of an inflammatory signal that includes interferon-gamma before the CD40 signal results in high levels of expression of interleukin-12 that was not seen in the absence of CD40L mRNA. All 4 preparations could induce expansion of primary MART-1-specific CD8+ T cells from healthy donors in vitro, but only the 2 processes receiving CD40L could induce interferon-gamma expression by those responder cells. Only DC electroporated with CD40L RNA after delivery of the inflammatory signal (PME-CD40L DC), could drive the long-term expansion of MART-1-reactive cells that displayed a CD28+/CD45RA- effector/memory phenotype with strong cytolytic activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779746     DOI: 10.1097/CJI.0b013e318183db02

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  16 in total

1.  Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

Authors:  Cynthia L Gay; Mark A DeBenedette; Irina Y Tcherepanova; Alicia Gamble; Whitney E Lewis; Anna B Cope; JoAnn D Kuruc; Kara S McGee; Mary F Kearney; John M Coffin; Nancie M Archin; Charles B Hicks; Joseph J Eron; Charles A Nicolette; David M Margolis
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-21       Impact factor: 2.205

2.  A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.

Authors:  Rémi J Creusot; Pearl Chang; Don G Healey; Irina Y Tcherepanova; Charles A Nicolette; C Garrison Fathman
Journal:  Mol Ther       Date:  2010-07-13       Impact factor: 11.454

Review 3.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 4.  Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.

Authors:  Rekha A Kumbla; Robert A Figlin; Edwin M Posadas
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

5.  Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.

Authors:  Jean-Pierre Routy; Mohamed-Rachid Boulassel; Bader Yassine-Diab; Charles Nicolette; Don Healey; Renu Jain; Claire Landry; Oleg Yegorov; Irina Tcherepanova; Tamara Monesmith; Lothar Finke; Rafick-Pierre Sékaly
Journal:  Clin Immunol       Date:  2009-11-04       Impact factor: 3.969

Review 6.  Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

Authors:  Susanna A Curtis; Justine V Cohen; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.945

7.  Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Authors:  Asim Amin; Arkadiusz Z Dudek; Theodore F Logan; Raymond S Lance; Jeffrey M Holzbeierlein; Jennifer J Knox; Viraj A Master; Sumanta K Pal; Wilson H Miller; Lawrence I Karsh; Irina Y Tcherepanova; Mark A DeBenedette; W Lee Williams; Douglas C Plessinger; Charles A Nicolette; Robert A Figlin
Journal:  J Immunother Cancer       Date:  2015-04-21       Impact factor: 13.751

8.  Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.

Authors:  Jacoba G Slagter-Jäger; Alexa Raney; Whitney E Lewis; Mark A Debenedette; Charles A Nicolette; Irina Y Tcherepanova
Journal:  Mol Ther Nucleic Acids       Date:  2013-05-07       Impact factor: 10.183

9.  The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.

Authors:  Irina Tcherepanova; Aijing Starr; Brad Lackford; Melissa D Adams; Jean-Pierre Routy; Mohamed Rachid Boulassel; David Calderhead; Don Healey; Charles Nicolette
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

10.  Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells.

Authors:  Stefanie Hoyer; Kerstin F Gerer; Isabell A Pfeiffer; Sabrina Prommersberger; Sandra Höfflin; Tanushree Jaitly; Luca Beltrame; Duccio Cavalieri; Gerold Schuler; Julio Vera; Niels Schaft; Jan Dörrie
Journal:  J Immunol Res       Date:  2015-12-28       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.